Authors:
ROBIEUX I
RUPOLO M
SPAZZAPAN S
FRATINO L
MILAN I
CONCA S
TOFFOLI G
ZAGONEL V
Citation: I. Robieux et al., PHARMACOKINETICS AND SAFETY OF IDARUBICIN AS A CONTINUOUS-INFUSION INELDERLY PATIENTS (EP) WITH NON-HODGKINS-LYMPHOMA (NHL), Annals of oncology, 9, 1998, pp. 73-73
Authors:
FRANCHIN G
MINATEL E
GOBITTI C
TALAMINI R
SARTOR G
CARUSO G
GRANDO G
POLITI D
GIGANTE M
TOFFOLI G
TROVO MG
BARZAN L
Citation: G. Franchin et al., RADIATION TREATMENT OF GLOTTIC SQUAMOUS-CELL CARCINOMA, STAGE-I AND STAGE-II - ANALYSIS OF FACTORS AFFECTING PROGNOSIS, International journal of radiation oncology, biology, physics, 40(3), 1998, pp. 541-548
Authors:
TOFFOLI G
RUSSO A
GALLO A
CERNIGOI C
MIOTTI S
SORIO R
TUMOLO S
BOIOCCHI M
Citation: G. Toffoli et al., EXPRESSION OF FOLATE BINDING-PROTEIN AS A PROGNOSTIC FACTOR FOR RESPONSE TO PLATINUM-CONTAINING CHEMOTHERAPY AND SURVIVAL IN HUMAN OVARIAN-CANCER, International journal of cancer, 79(2), 1998, pp. 121-126
Authors:
CORONA G
GIANNINI F
FABRIS M
TOFFOLI G
BOIOCCHI M
Citation: G. Corona et al., ROLE OF FOLATE RECEPTOR AND REDUCED FOLATE CARRIER IN THE TRANSPORT OF 5-METHYLTETRAHYDROFOLIC ACID IN HUMAN OVARIAN-CARCINOMA CELLS, International journal of cancer, 75(1), 1998, pp. 125-133
Authors:
CORONA G
TOFFOLI G
FABRIS M
VIEL A
ZARRELLI A
DONADA C
BOIOCCHI M
Citation: G. Corona et al., HOMOCYSTEINE ACCUMULATION IN HUMAN OVARIAN-CARCINOMA ASCITIC CYSTIC FLUIDS POSSIBLY CAUSED BY METABOLIC ALTERATION OF THE METHIONINE CYCLE IN OVARIAN-CARCINOMA CELLS/, European journal of cancer, 33(8), 1997, pp. 1284-1290
Authors:
SORIO R
TOFFOLI G
ROBIEUX I
RIMONDI G
AITA P
CORONA G
CRIVELLARI D
COLUSSI AM
TUMOLO S
Citation: R. Sorio et al., DOSE-FINDING AND PHARMACOKINETIC (PK) STUDY OF DAILY ORAL IDARUBICIN (IDA) IN METASTATIC BREAST-CANCER (MBC), European journal of cancer, 33, 1997, pp. 1136-1136
Authors:
TOFFOLI G
ROBIEUX I
FANTIN D
GIGANTE M
FRUSTACI S
NICOLOSI GL
DECICCO M
BOIOCCHI M
Citation: G. Toffoli et al., NONLINEAR PHARMACOKINETICS OF HIGH-DOSE INTRAVENOUS VERAPAMIL, British journal of clinical pharmacology, 44(3), 1997, pp. 255-260
Citation: G. Ravalico et al., PULSATILE OCULAR BLOOD-FLOW VARIATIONS WITH AXIAL LENGTH AND REFRACTIVE ERROR, Ophthalmologica, 211(5), 1997, pp. 271-273
Authors:
TOFFOLI G
CORONA G
SORIO R
BERTOLA A
BOIOCCHI M
Citation: G. Toffoli et al., REVERSAL ACTIVITY OF CYCLOSPORINE-A AND ITS METABOLITES M1, M17 AND M21 IN MULTIDRUG-RESISTANT CELLS, International journal of cancer, 71(5), 1997, pp. 900-906
Authors:
TOFFOLI G
SORIO R
GIGANTE M
CORONA G
GALLIGIONI E
BOIOCCHI M
Citation: G. Toffoli et al., CYCLOSPORINE-A AS A MULTIDRUG-RESISTANT MODULATOR IN PATIENTS WITH RENAL-CELL CARCINOMA TREATED WITH TENIPOSIDE, British Journal of Cancer, 75(5), 1997, pp. 715-721
Authors:
ROBIEUX I
AITA P
SORIO R
TOFFOLI G
BOIOCCHI M
Citation: I. Robieux et al., DETERMINATION OF UNBOUND ETOPOSIDE CONCENTRATION IN ULTRAFILTERED PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUOROMETRIC DETECTION, Journal of chromatography B. Biomedical applications, 686(1), 1996, pp. 35-41
Citation: G. Toffoli et al., INHIBITION OF PGP ACTIVITY AND CELL CYCLE-DEPENDENT CHEMOSENSITIVITY TO DOXORUBICIN IN THE MULTIDRUG-RESISTANT LOVO HUMAN COLON-CANCER CELL-LINE, European journal of cancer, 32A(9), 1996, pp. 1591-1597
Authors:
TOFFOLI G
CORONA G
SIMONE F
GIGANTE M
DEANGELI S
BOIOCCHI M
Citation: G. Toffoli et al., CELLULAR PHARMACOLOGY OF IDARUBICINOL IN MULTIDRUG-RESISTANT LOVO CELL-LINES, International journal of cancer, 67(1), 1996, pp. 129-137
Authors:
TOFFOLI G
SORIO R
GALLIGIONI E
RITOSSI D
COLUSSI A
TROVO M
BOIOCCHI M
Citation: G. Toffoli et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF TENIPOSIDE (VM26) COADMINISTERED WITH CYCLOSPORINE-A (CSA) IN PATIENTS WITH METASTATIC RENAL-CELL CANCER (RCC), European journal of cancer, 31A, 1995, pp. 135-135
Authors:
GIGANTE M
SORIO R
COLUSSI AM
SANDRIN A
DEAPPOLLONIA L
GALLIGIONI E
FRESCHI A
TALAMINI R
TOFFOLI G
BOIOCCHI M
Citation: M. Gigante et al., EFFECT OF CYCLOSPORINE ON TENIPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH RENAL-CELL CANCER, Anti-cancer drugs, 6(3), 1995, pp. 479-482
Authors:
TOFFOLI G
FRANCHIN G
BARZAN L
CERNIGOI C
CARBONE A
SULFARO S
FRANCESCHI S
BOIOCCHI M
Citation: G. Toffoli et al., BRIEF REPORT - PROGNOSTIC IMPORTANCE OF CELLULAR DNA CONTENT IN T1-2 N0 LARYNGEAL SQUAMOUS-CELL CARCINOMAS TREATED WITH RADIOTHERAPY, The Laryngoscope, 105(6), 1995, pp. 649-652
Authors:
BORTOLUZZI F
VALENTINI M
CERNIGOI C
TOFFOLI G
BOIOCCHI M
POLETTI M
SOZZI M
FORNASARIG M
CANNIZZARO R
BERTOLISSI E
Citation: F. Bortoluzzi et al., DNA FLOW CYTOMETRIC EVALUATION OF CELL-CYCLE DISTRIBUTION IN ULCERATIVE-COLITIS - A PROPOSED METHOD FOR ASSESSING SEVERITY OF DISEASE, Gut, 36(1), 1995, pp. 50-54
Citation: M. Gigante et al., PHARMACOKINETICS OF DOXORUBICIN CO-ADMINISTERED WITH HIGH-DOSE VERAPAMIL, British Journal of Cancer, 71(1), 1995, pp. 134-136
Authors:
TOFFOLI G
SIMONE F
CORONA G
RASCHACK M
CAPPELLETTO B
GIGANTE M
BOIOCCHI M
Citation: G. Toffoli et al., STRUCTURE-ACTIVITY RELATIONSHIP OF VERAPAMIL ANALOGS AND REVERSAL OF MULTIDRUG-RESISTANCE, Biochemical pharmacology, 50(8), 1995, pp. 1245-1255
Authors:
TOFFOLI G
DOGLIONI C
CERNIGOI C
FRUSTACI S
PERIN T
CANAL B
BOIOCCHI M
Citation: G. Toffoli et al., P53 OVEREXPRESSION IN HUMAN SOFT-TISSUE SARCOMAS - RELATION TO BIOLOGICAL AGGRESSIVENESS, Annals of oncology, 5(2), 1994, pp. 167-172
Citation: G. Toffoli et al., COMPARISON OF MECHANISMS RESPONSIBLE FOR RESISTANCE TO IDARUBICIN ANDDAUNORUBICIN IN MULTIDRUG-RESISTANT LOVO CELL-LINES, Biochemical pharmacology, 48(10), 1994, pp. 1871-1881
Authors:
TOFFOLI G
TUMIOTTO L
GIGANTE M
DALLARCHE MG
PERIN T
BOIOCCHI M
Citation: G. Toffoli et al., INCREASED CHEMOSENSITIVITY TO DOXORUBICIN OF INTRINSICALLY MULTIDRUG-RESISTANT HUMAN COLON-CARCINOMA CELLS BY PROLONGED EXPOSURE TO VERAPAMIL, European journal of cancer, 29A(12), 1993, pp. 1776-1778
Authors:
TOFFOLI G
TUMIOTTO L
GIGANTE M
PERIN T
BISCONTIN G
BOIOCCHI M
Citation: G. Toffoli et al., DOXORUBICIN, VINCRISTINE, AND ACTINOMYCIN-D, BUT NOT TENIPOSIDE, REQUIRE LONG-LASTING UNINTERRUPTED VERAPAMIL PRESSURE TO OVERCOME DRUG-RESISTANCE IN MULTIDRUG-RESISTANT CELLS, Cancer detection and prevention, 17(3), 1993, pp. 425-432